Mounjaro®
Starting from £179.99/mo
Start journey Learn moreHair shedding on Mounjaro is real, but it is almost never caused by the medicine itself — and supplements alone are unlikely to fix it. The clinical term is telogen effluvium: a temporary disruption to the hair-growth cycle triggered by rapid weight loss and reduced calorie intake, not by tirzepatide directly. Understanding that distinction matters before reaching for any supplement. As a prescription-only medicine, Mounjaro is dispensed only after a clinical assessment by a prescriber who can also discuss side effects particular to your circumstances.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
This is understandable. You start a new medicine, weight begins to fall, and a few months later the shower drain tells a different story. It is easy to connect those two things directly, new injection, hair loss, cause and effect. But the relationship is more indirect than that, and recognising it changes what you do next.
Tirzepatide does not appear to have a direct toxic effect on hair follicles. What it does do, very effectively, is reduce appetite. When calorie intake drops sharply and body weight falls quickly, the body reads this as physiological stress. Hair follicles respond by shifting from active growth into a resting phase, then shedding those resting hairs simultaneously. That shedding typically appears two to four months after the triggering event, which is why it seems to follow the injection so neatly.
The NHS patient information for tirzepatide lists hair loss among the known side effects, acknowledging it occurs in some people during treatment. Researchers and clinicians reviewing the SURMOUNT programme data noted that the pattern matches telogen effluvium rather than drug-induced follicular damage. This distinction is not merely academic: it points directly to what actually helps.
You can read a fuller account of why this happens on our page about Mounjaro and hair loss, and if you are specifically looking into how Mounjaro side effects relate to hair loss, that page goes into the clinical detail behind the shedding pattern.
If the root cause is nutritional stress rather than a direct drug effect, it follows that correcting nutritional gaps is genuinely useful. The difficulty is that most people reaching for supplements do not know which gaps, if any, they actually have.
Hair follicles are metabolically active and disproportionately sensitive to protein insufficiency. On a significantly reduced-calorie diet, protein is often the first thing to fall short. Adequate daily protein (guidance from dietitians typically points to at least 1.2 g per kilogram of body weight, though a prescriber or registered dietitian can advise on your specific target) appears to be the single most protective nutritional factor during weight-loss-associated shedding.
Iron deficiency is the next common culprit, particularly in women. Zinc and biotin deficiencies are documented causes of hair loss, though true biotin deficiency is uncommon in people eating a varied diet. A more detailed look at which supplements are best supported by evidence covers these nutrients specifically, including when a blood test makes sense before spending money on capsules.
The honest answer: if you have no documented deficiency, high-dose supplementation with biotin or zinc is unlikely to accelerate recovery and, in the case of zinc in particular, excessive intake can be counterproductive. Correcting a real gap helps. Supplementing beyond adequacy does not.
Your prescriber is the right person to advise on whether a blood panel is worth running and what any results mean for your supplement choices, this is something our team discusses as part of ongoing aftercare.
Telogen effluvium is self-limiting in the majority of cases. Once the physiological stress settles (weight stabilises, calorie intake reaches a sustainable level) hair follicles re-enter the growth phase. Visible shedding typically slows within three to six months of stabilisation, though full regrowth of shed hairs takes longer because the growth cycle itself runs to 12–18 months.
If you are mid-titration on Mounjaro, weight may still be falling when shedding peaks, which can make the timeline feel worse. That is not a sign of permanent damage; it is timing. Slowing your titration to allow weight to stabilise earlier is a clinical decision, not something to do unilaterally, but a reasonable thing to raise with your prescriber.
Practical steps alongside any supplement: keep protein intake consistent, stay hydrated, avoid aggressive heat styling or tight hairstyles during the shedding phase, and be patient with recovery. If you want to understand what hair loss from Mounjaro typically looks like in practice, including how people experience the shedding phase and what recovery involves, that page covers the pattern in more detail. A mild, gentle shampoo is fine; the evidence for specialist 'growth shampoos' is thin.
For a broader look at how hair changes fit within the full side-effect picture of tirzepatide, the Mounjaro side effects page covers the clinical spectrum.
Most Mounjaro-related hair shedding does not require urgent medical attention, but some patterns do warrant a conversation sooner rather than later.
See a GP or contact your prescriber promptly if: shedding is severe or sudden rather than gradual; you notice bald patches rather than diffuse thinning; shedding continues beyond six months with no sign of slowing; you develop scalp symptoms such as itching, redness or scaling; or hair loss is accompanied by other unexplained symptoms such as fatigue, cold intolerance or swollen lymph nodes. These patterns can indicate conditions unrelated to weight loss (thyroid disorders, alopecia areata or nutritional anaemia among them) that deserve their own investigation. Our page on Mounjaro hair loss treatment outlines the options available when shedding does not resolve on its own and a more active approach is appropriate.
If you experience any side effect you believe is linked to your treatment, you can report it directly through the MHRA's Yellow Card scheme. Yellow Card reporting is how post-market safety signals are captured, and the MHRA takes reports from patients directly, you do not need to go through a doctor first. Mounjaro carries a Black Triangle (▼) designation, meaning the MHRA is actively collecting additional safety data; your report genuinely contributes to that evidence base.
If you have questions about what you are experiencing or whether your symptoms need attention, our support team is available seven days a week, and our clinical team provides prescriber-level oversight throughout your treatment. Side effects are a normal part of any clinical conversation, raising them is always the right call.
If you would like to discuss Mounjaro suitability, side effects and what treatment involves before committing to anything, start your free consultation with our prescribers.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.